<?xml version="1.0" encoding="UTF-8"?>
<div id="RE1" response-type="reply" class="response" xmlns="http://www.w3.org/1999/xhtml">
 <front-stub xmlns="">
  <article-id pub-id-type="doi">10.3346/jkms.2020.35.e89</article-id>
  <title-group>
   <article-title>The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR</article-title>
  </title-group>
  <contrib-group>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3553-0058</contrib-id>
    <name>
     <surname>Lim</surname>
     <given-names>Jaegyun</given-names>
    </name>
    <xref ref-type="aff" rid="A2">1</xref>
   </contrib>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4320-2644</contrib-id>
    <name>
     <surname>Jeon</surname>
     <given-names>Seunghyun</given-names>
    </name>
    <xref ref-type="aff" rid="A3">2</xref>
   </contrib>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7261-3365</contrib-id>
    <name>
     <surname>Shin</surname>
     <given-names>Hyun-Young</given-names>
    </name>
    <xref ref-type="aff" rid="A4">3</xref>
   </contrib>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4148-9116</contrib-id>
    <name>
     <surname>Kim</surname>
     <given-names>Moon Jung</given-names>
    </name>
    <xref ref-type="aff" rid="A2">1</xref>
   </contrib>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9650-6353</contrib-id>
    <name>
     <surname>Seong</surname>
     <given-names>Yu Min</given-names>
    </name>
    <xref ref-type="aff" rid="A5">4</xref>
   </contrib>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3042-1557</contrib-id>
    <name>
     <surname>Lee</surname>
     <given-names>Wang Jun</given-names>
    </name>
    <xref ref-type="aff" rid="A6">5</xref>
   </contrib>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2003-6492</contrib-id>
    <name>
     <surname>Choe</surname>
     <given-names>Kang-Won</given-names>
    </name>
    <xref ref-type="aff" rid="A7">6</xref>
   </contrib>
   <contrib contrib-type="author">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4368-9878</contrib-id>
    <name>
     <surname>Kang</surname>
     <given-names>Yu Min</given-names>
    </name>
    <xref ref-type="aff" rid="A7">6</xref>
   </contrib>
   <contrib contrib-type="author" corresp="yes">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7867-8434</contrib-id>
    <name>
     <surname>Lee</surname>
     <given-names>Baeckseung</given-names>
    </name>
    <xref ref-type="aff" rid="A8">7</xref>
   </contrib>
   <contrib contrib-type="author" corresp="yes">
    <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3178-6272</contrib-id>
    <name>
     <surname>Park</surname>
     <given-names>Sang-Joon</given-names>
    </name>
    <xref ref-type="aff" rid="A9">8</xref>
   </contrib>
  </contrib-group>
  <aff id="A2">
   <label>1</label>Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, 
   <country>Korea</country>.
  </aff>
  <aff id="A3">
   <label>2</label>New Horizon Cancer Institute, Myongji Hospital, Goyang, 
   <country>Korea</country>.
  </aff>
  <aff id="A4">
   <label>3</label>Department of Family Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, 
   <country>Korea</country>.
  </aff>
  <aff id="A5">
   <label>4</label>Department of Internal Medicine, Myongji Hospital, Goyang, 
   <country>Korea</country>.
  </aff>
  <aff id="A6">
   <label>5</label>Office of Chief Executive Officer and Chairman, Department of General Surgery, Myongji Hospital, Goyang, 
   <country>Korea</country>.
  </aff>
  <aff id="A7">
   <label>6</label>Department of Infectious Diseases, Myongji Hospital, Goyang, 
   <country>Korea</country>.
  </aff>
  <aff id="A8">
   <label>7</label>CancerROP, Seoul, 
   <country>Korea</country>.
  </aff>
  <aff id="A9">
   <label>8</label>Department of Pulmonary and Critical Care Medicine, Myongji Hospital, Goyang, 
   <country>Korea</country>.
  </aff>
  <author-notes>
   <corresp>Address for Correspondence: Sang-Joon Park, MD, PhD. Department of Pulmonary and Critical Care Medicine, Myongji Hospital, 55 Hwasu-ro 14-beon-gil, Deogyang-gu, Goyang 10475, Republic of Korea. 
    <email>drjoseph@mjh.or.kr</email>
   </corresp>
   <corresp>Address for Correspondence: Baeckseung Lee, PhD. CancerROP, 173 Digital-ro, Geumcheon-gu, Seoul 08511, Republic of Korea. 
    <email>baeckseung@gmail.com</email>
   </corresp>
  </author-notes>
  <pub-date pub-type="epub">
   <day>20</day>
   <month>2</month>
   <year>2020</year>
  </pub-date>
  <pub-date pub-type="collection">
   <day>24</day>
   <month>2</month>
   <year>2020</year>
  </pub-date>
  <volume>35</volume>
  <issue>7</issue>
  <elocation-id>e89</elocation-id>
  <history>
   <date date-type="received">
    <day>19</day>
    <month>2</month>
    <year>2020</year>
   </date>
   <date date-type="accepted">
    <day>19</day>
    <month>2</month>
    <year>2020</year>
   </date>
  </history>
 </front-stub>
 <body xmlns="">
  <p>I appreciate Dr. Kim's interest in our article entitled “Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea” and we would like to thank him for his critical comment to improve our article.
   <xref rid="BC1" ref-type="bibr">1</xref>
  </p>
  <p>Our report focused on the decrease of virus loads and the alleviation of the patient's symptoms during lopinavir/ritonavir (LPV/r) administration. As Dr. Kim mentioned in the letter, our findings did not prove whether it was caused by the natural course of the disease or by the effects of drug and there is no clinical evidence. We did not argue that the decline of viral load was caused solely by the antiviral agent we used and emphasize that broader clinical trials will be needed to reveal the therapeutic efficacy of this study of this antiviral agent.</p>
  <p>Unfortunately, no drug or vaccine has yet been approved to treat coronavirus disease 2019 (COVID-19). Favipiravir, ribavirin, remdesivir and galidesivir could be good candidates as potential antiviral agents for the treatment.
   <xref rid="BC2" ref-type="bibr">2</xref> And many clinical trials on anti-HIV drugs, LPV/r and experimental antiviral agent, remdesevir are in the development process in China (
   <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT04261907" xmlns:xlink="http://www.w3.org/1999/xlink">http://clinicaltrials.gov/show/NCT04261907</ext-link>, 
   <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT04255017" xmlns:xlink="http://www.w3.org/1999/xlink">http://clinicaltrials.gov/show/NCT04255017</ext-link>).
   <xref rid="BC2" ref-type="bibr">2</xref> There are reports that remdesevir and antimalarial agent, chloroquine effectively inhibited SARS-CoV-2 in vitro.
   <xref rid="BC3" ref-type="bibr">3</xref> If these clinical studies are successful, they can provide us with more efficient treatment options and suggest better choices for COVID-19 treatment in high-risk groups (elderly patients or patients with underlying diseases).
  </p>
  <p>What we discussed in this report is the relative quantitation of virus loads with qRT-PCR during LPV/r administration and alleviation of the patient's symptoms. Therefore, if better and broader clinical trials monitored by qRT-PCRs are designed and performed during antiviral agent administration, more accurate viral kinetics of COVID-19 will be obtained and the effects of the drug will be elucidated more clearly.</p>
  <p>We are hoping that the outbreak may subside in a couple of months, with the consistent efforts to prevent the spread of COVID-19 worldwide, as in the cases of SARS and MERS. In the meantime we need to make great efforts to develop antiviral agents to treat COVID-19 as well.</p>
 </body>
 <back xmlns="">
  <fn-group>
   <fn fn-type="COI-statement">
    <p>
     <bold>Disclosure:</bold> The authors have no potential conflicts of interest to disclose.
    </p>
   </fn>
  </fn-group>
  <ref-list>
   <ref id="BC1">
    <label>1</label>
    <element-citation publication-type="journal">
     <person-group person-group-type="author">
      <name>
       <surname>Lim</surname>
       <given-names>J</given-names>
      </name>
      <name>
       <surname>Jeon</surname>
       <given-names>S</given-names>
      </name>
      <name>
       <surname>Shin</surname>
       <given-names>HY</given-names>
      </name>
      <name>
       <surname>Kim</surname>
       <given-names>MJ</given-names>
      </name>
      <name>
       <surname>Seong</surname>
       <given-names>YM</given-names>
      </name>
      <name>
       <surname>Lee</surname>
       <given-names>WJ</given-names>
      </name>
      <etal/>
     </person-group>
     <article-title>Case of the index patient who caused tertiary transmission of Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR</article-title>
     <source>J Korean Med Sci</source>
     <year>2020</year>
     <volume>35</volume>
     <issue>6</issue>
     <elocation-id>e79</elocation-id>
     <pub-id pub-id-type="pmid">32056407</pub-id>
    </element-citation>
   </ref>
   <ref id="BC2">
    <label>2</label>
    <element-citation publication-type="journal">
     <person-group person-group-type="author">
      <name>
       <surname>Li</surname>
       <given-names>G</given-names>
      </name>
      <name>
       <surname>Clercq</surname>
       <given-names>ED</given-names>
      </name>
     </person-group>
     <article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title>
     <source>Nat Rev Drug Discov</source>
     <comment>Forthcoming</comment>
     <year>2020</year>
     <pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id>
    </element-citation>
   </ref>
   <ref id="BC3">
    <label>3</label>
    <element-citation publication-type="journal">
     <person-group person-group-type="author">
      <name>
       <surname>Wang</surname>
       <given-names>M</given-names>
      </name>
      <name>
       <surname>Cao</surname>
       <given-names>R</given-names>
      </name>
      <name>
       <surname>Zhang</surname>
       <given-names>L</given-names>
      </name>
      <name>
       <surname>Yang</surname>
       <given-names>X</given-names>
      </name>
      <name>
       <surname>Liu</surname>
       <given-names>J</given-names>
      </name>
      <name>
       <surname>Xu</surname>
       <given-names>M</given-names>
      </name>
      <etal/>
     </person-group>
     <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>
     <source>Cell Res</source>
     <comment>Forthcoming</comment>
     <year>2020</year>
     <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>
    </element-citation>
   </ref>
  </ref-list>
 </back>
</div>
